ArticleJournal of military, veteran and family health2025
Evaluation of rTMS for treatment-resistant PTSD and depression in active/retired Canadian Armed Forces and RCMP patients.
Article in Journal of military, veteran and family health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Repetitive transcranial magnetic stimulation (rTMS) is an effective, non-invasive treatment option for treatment-resistant posttraumatic stress disorder (TR PTSD) and treatment-resistant depression (TRD). This study assesses left-sided high-frequency (LSHF) rTMS on symptoms of Canadian Armed Forces (CAF) and Royal Canadian Mounted Police (RCMP) members with TRD and TR PTSD at the Carewest Operational Stress Injury clinic. Methods: This feasibility study used a quantitative longitudinal design. The study population included 28 CAF and RCMP members with TR PTSD and TRD, defined as lack of response to two antidepressants and one evidence-based psychotherapy. Patients concurrently undertook biological and psychological treatment as usual. Up to 30 sessions of LSHF rTMS were provided; non-responders switched to right-sided low-frequency (RSLF) rTMS after 20 sessions. Depression and PTSD symptoms were quantified using the PTSD Checklist for DSM-5 (PCL-5) and Patient Health Questionnaire-9 (PHQ-9) before treatment, every 10th session, and at completion. Outcomes were analyzed with one-way repeated-measures analysis of variance. Results: PHQ-9 scores decreased ( Discussion: These findings support the efficacy of rTMS for reducing symptoms of TRD and TR PTSD in this population. Larger studies with sham rTMS comparison, blinding, and randomization are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.